Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer

Clinical trial NCT06801236 · RECRUITING

Trial details

NCT number: NCT06801236
Sponsor: Acerand Therapeutics (Hong Kong) Limited
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Prostate Cancer (Adenocarcinoma)mCRPC (Metastatic Castration-resistant Prostate Cancer)

Start date: 2025-05-12
Primary completion: 2028-12-31
Enrollment: 88

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.